Effect of prenatal administration of venlafaxine on postnatal development of rat offspring
By: Michal Dubovický, Eszter Császárová, Zuzana Brnoliaková, Eduard Ujházy, Jana Navarová and Mojmír Mach
Open Access
|Nov 2012References
- Bellantuono C, Migliarese G, Maggioni F, Imperadore G. (2007) Anridepressant drugs and breastfeeding.: 29-42.
- Chung TK, Lau TK, Yip AS, Chiu HF, Lee DT. (2001). Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes.: 830-834.
- Da-Silva VA, Alterburg SP, Malheiros LR, Thomaz TG, Lindsey CJ. (1999). Postnatal development of rats exposed to fl uoxetine or venlafaxine during the third week of pregnancy.: 93-98.
- DeSantis DT, Schmaltz LW. (1984). The mother-litter relationship in developmental rat studies: cannibalism vs caring.: 255-62
- Dubovický M, Kovačovský P, Ujházy E, Navarová J, Brucknerová I, Mach M. (2008). Evaluation of developmental neurotoxicity: some important issues focused on neurobehavioral development: 206-210.
- Dubovický M. (2010). Neurobehavioral manifestations of developmental impairment of the brain.: 59-67.
- Evans J, Heron J, Francomb H, Oke S, Golding J. (2001). Cohort study of depressed mood during pregnancy and after childbirth.: 257-260.
- Favreliere S, Nourrisson A, Jaafari N, Pérault Pochat MC (2010). Treatment of depressed pregnant women by selective serotonin reuptake inhibitors: risk for the foetus and the newborn.: D133-D138.
- Freeman MP. (2011). Antidepressant medication treatment during pregnancy: prevalence of use, clinical implications, and alternatives.: 977-978.
- Gentile S. (2005). SSRIs in pregnancy and lactation: emphasis on neurobehavioral outcome.: 623-633.
- Melville JL, Gavin A, Gup Y, Fan MY, Katon WJ. (2010). Depressive disorders during pregnancy: prevalence and risk factors in a large urban sample..: 1064-1070.
- Morrison JL, Riggs KW, Rurak DW. (2005). Fluoxetine during pregnancy: impact on fetal development.: 641-650.
- Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL. (2005). Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications.: 2372-2383.
- Nonacs R, Cohen LS. (2002). Depression during pregnancy: diagnosis and treatment options.: 24-30.
- Oberlander TF, Papsdorf M, Brain UM, Misri S, Ross C, Grunau RE. (2010). Prenatal effect of selective serotonin reuptake inhibitor antidepressants, serotonin, transporter promoter genotype (SLC6A4) and maternal mood on child behavior at 3 years of age.: 444-451.
- OECD. (1995). Guideline for the testing of chemicals, Draft proposal for a new guideline 426, Developmental Neurotoxicity Study.
- Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. (2007). Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more eff ective than the selective serotonin reuptake inhibitors in treating major depression disorder? A meta-analysis of studies of newer agents.: 1217-1227.
- Patil AS, Kuller JA, Rhee EH. (2011) Antidepressants in pregnancy: a review of commonly prescribed medications.: 777-8.
- Pilar-Cuéllar F, Vidal R, Pazos A. (2012). Subchronic treatment with fluoxetine and the 5-HT(2A) antagonist ketanserin upregulates hippocampal BDNF and β-catenin in parallel with antidepressant-like eff ect..(4b): 1046-57
- Rampono J, Simmer K, Ilett KF, Hackett LP, Doherty DA, Elliot R, Kok CH, Coenen A, Froman T. (2009). Placental transfer of SSRI and SNRI antidepressants and eff ects on the neonate.: 95-100.
- Sumner SC, Fennell TR, Snyder RW, Taylor GF, Lewin AH. (2010). Distribution of carbon-14 labeled C60 ([14C]C60) in the pregnant and in the lactating dam and the eff ect of C60 exposure on the biochemical profi le of urine.: 354-60.
- Tuccori M, Testi A, Antonioli L, Fomai M, Montagnani S, Ghisu N, Colucci R, Corona T, Blandizzi C, Del Tacca M. (2009). Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review.: 1426-1453.
- Weikop P, Kehr J, Scheel-Krüger J. (2007). Reciprocal eff ects of combined administration of serotonin, noradrenaline and dopamine reuptake inhibitors on serotonin and dopamine levels in the rat prefrontal cortex: the role of 5-HT1A receptors.: 795-804.
- Wellington K, Perry C. (2001). Venlafaxine extended-release: a review of its use in the management of major depression.: 643-69.
Language: English
Page range: 92 - 97
Published on: Nov 9, 2012
Published by: Slovak Academy of Sciences, Institute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2012 Michal Dubovický, Eszter Császárová, Zuzana Brnoliaková, Eduard Ujházy, Jana Navarová, Mojmír Mach, published by Slovak Academy of Sciences, Institute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine
This work is licensed under the Creative Commons License.